Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve efficacy outcomes and increased BTK specificity may minimize off-target inhibition-related toxicities. PATIENTS AND METHODS ALPINE (ClinicalTrials.gov...

  • 123456 Profile photo of Madelyn

    Interim analysis of a phase III of zanubrutinib vs ibrutinib shows improved response rates, 12 month PFS and better safety with zanubrutinib. There was decreased major bleeding, cardiac events and AEs leading to discontinuation. Afib was lower at 2.5% vs 10%.